Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HuCART-meso cells + VCN-01 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HuCART-meso cells | anti-MSLN CAR-T Cells | HuCART-meso cells are T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets mesothelin and contains the zeta chain of CD3 (CD3zeta) and other costimulatory domains, which potentially leads to increased antitumor immune response (PMID: 26973126, PMID: 31420241). | ||
VCN-01 | VCN-01 is a replication-competent oncolytic adenovirus that may lead to decreased tumor cell viability and reduced tumor growth (PMID: 26603261), particularly in tumors with a dysfunctional RB1 pathway (PMID: 30674657). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05057715 | Phase I | HuCART-meso cells + VCN-01 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Recruiting | USA | 0 |